Abstract
A neoadjuvant approach relying on the administration of combined anti-CTLA-4–anti-PD-1 treatment before lymph node surgery is evaluated in two phase 1 trials. Encouraging clinical, pathological and immunological responses to neoadjuvant therapy were observed, suggesting that this concept warrants further exploration; however, any future approach must address the unacceptably high toxicity of the regimens evaluated in these trials.
Original language | English |
---|---|
Pages (from-to) | 1645-1648 |
Number of pages | 4 |
Journal | Nature Medicine |
Volume | 24 |
Issue number | 11 |
DOIs | |
Publication status | Published - 1 Nov 2018 |
Externally published | Yes |